Cargando…
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
The metastatic burden is a critical factor for decision‐making in the treatment of metastatic hormone‐sensitive prostate cancer (HSPC). This study aimed to develop and validate a novel risk model for survival in patients with de novo low‐ and high‐burden metastatic HSPC. The retrospective observatio...
Autores principales: | Shiota, Masaki, Terada, Naoki, Kitamura, Hiroshi, Kojima, Takahiro, Saito, Toshihiro, Yokomizo, Akira, Kohei, Naoki, Goto, Takayuki, Kawamura, Sadafumi, Hashimoto, Yasuhiro, Takahashi, Atsushi, Kimura, Takahiro, Tabata, Ken‐ichi, Tomida, Ryotaro, Hashimoto, Kohei, Sakurai, Toshihiko, Shimazui, Toru, Sakamoto, Shinichi, Kamiyama, Manabu, Tanaka, Nobumichi, Mitsuzuka, Koji, Kato, Takuma, Narita, Shintaro, Yasumoto, Hiroaki, Teraoka, Shogo, Kato, Masashi, Osawa, Takahiro, Nagumo, Yoshiyuki, Matsumoto, Hiroaki, Enokida, Hideki, Sugiyama, Takayuki, Kuroiwa, Kentaro, Inoue, Takahiro, Sugimoto, Mikio, Mizowaki, Takashi, Kamoto, Toshiyuki, Nishiyama, Hiroyuki, Eto, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409413/ https://www.ncbi.nlm.nih.gov/pubmed/34145921 http://dx.doi.org/10.1111/cas.15038 |
Ejemplares similares
-
Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients
por: Shiota, Masaki, et al.
Publicado: (2021) -
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer
por: Terada, Naoki, et al.
Publicado: (2020) -
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
por: Osawa, Takahiro, et al.
Publicado: (2020) -
Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022) -
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
por: Mukai, Shoichiro, et al.
Publicado: (2020)